{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nonmyeloablative+allogeneic+hematopoietic+stem+cell+transplantation", "query": { "intervention": "nonmyeloablative allogeneic hematopoietic stem cell transplantation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 310, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nonmyeloablative+allogeneic+hematopoietic+stem+cell+transplantation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T19:59:31.696Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01181271", "title": "Tandem Auto-Allo Transplant for Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse, Large B-Cell, Lymphoma", "Lymphoma, Low-Grade", "T-Cell Lymphoma", "Mantle-Cell Lymphoma", "Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Busulfan (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Etoposide (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Cyclophosphamide (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Mesna (prior to AUTO transplant)", "type": "DRUG" }, { "name": "autologous (auto) peripheral blood stem cell transplantation", "type": "OTHER" }, { "name": "Neupogen", "type": "DRUG" }, { "name": "Fludarabine (conditioning for ALLO Transplant)", "type": "DRUG" }, { "name": "Busulfan (conditioning for ALLO Transplant)", "type": "DRUG" }, { "name": "non-myeloablative allogeneic (allo) transplant", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2010-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01181271" }, { "nct_id": "NCT00397813", "title": "Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ring Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2006-01", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 3, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397813" }, { "nct_id": "NCT04761770", "title": "Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Myeloproliferative Neoplasms", "Chronic Myelomonocytic Leukemia", "Atypical Chronic Myeloid Leukemia", "Myelodysplastic/Myeloproliferative Overlapping Syndrome" ], "interventions": [ { "name": "Geriatric assessment (GA) pre-transplant", "type": "OTHER" }, { "name": "conditioning regimen", "type": "DRUG" }, { "name": "Allogeneic CD34+ selected stem cells", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 33, "start_date": "2021-02-15", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761770" }, { "nct_id": "NCT03995901", "title": "A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transplanted Organ Rejection" ], "interventions": [ { "name": "FCR001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Talaris Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-10-25", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 18, "location_summary": "Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03995901" }, { "nct_id": "NCT00001832", "title": "Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Neoplasm Metastasis" ], "interventions": [ { "name": "gp100:209-217 (210M)", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "MART-1:26-35(27L)", "type": "DRUG" }, { "name": "Abl cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GCSF (Growth colony stimulating factor)", "type": "BIOLOGICAL" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 170, "start_date": "1999-08", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001832" }, { "nct_id": "NCT00909948", "title": "Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin's Lymphoma", "Hodgkin Disease", "Multiple Myeloma" ], "interventions": [ { "name": "Fludarabine and total body irradiation", "type": "OTHER" }, { "name": "Total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2008-11", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909948" }, { "nct_id": "NCT01118091", "title": "Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Skin Cancer", "Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "CD8 enriched Young TIL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-04", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118091" }, { "nct_id": "NCT00041288", "title": "Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2001-10", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 19, "location_summary": "Denver, Colorado • Newark, Delaware • Orlando, Florida + 15 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041288" }, { "nct_id": "NCT01490723", "title": "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "111In Ibritumomab", "type": "DRUG" }, { "name": "Planar Scintigraphy Imaging", "type": "PROCEDURE" }, { "name": "90Y IbritumomabTiuxetan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2013-01", "completion_date": "2019-04-24", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490723" }, { "nct_id": "NCT00383994", "title": "Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Leukemia", "Transplantation, Stem Cell", "Lymphoid Malignancies", "Disorder Related to Transplantation" ], "interventions": [ { "name": "GM-CSF", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "NK Cell Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 6, "start_date": "2006-09", "completion_date": "2019-07-22", "has_results": false, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-10T19:59:31.696Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00383994" } ] }